14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
STEM vs DNA: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
DNA Captures Overall Composite Edge (52.1 HOLD vs 42.4 HOLD), While STEM Leads 4–2 on Growth & Valuation Pillars
DNA Overall Winner
6-Pillar Tally: STEM 4 – 2 DNA
Matrix Metrics: STEM 3 – 5 DNA
As of Nov 20, 2026, Ginkgo Bioworks Holdings, Inc. (DNA) captures the overall head-to-head institutional edge over Stem, Inc. (STEM) on higher Unified Composite conviction (52.1/100 HOLD vs. 42.4/100 HOLD) after splitting the core matrix 5–3 (led by Valuation Multiples, Options & Positioning), while STEM wins 4–2 across the 6-pillar growth and valuation breakdown. STEM trades at $0.64 (N/M Forward P/E, -12.1% operating margin) versus DNA at $7.46 (N/M Forward P/E, -202.5% operating margin).
Growth vs. Quality Trade-Off: DNA earns the overall head-to-head edge with a stronger Unified Composite Score (52.1/100 HOLD vs. STEM 42.4/100 HOLD) and 3.12β · 152% Vol risk profile, whereas STEM leads top-line expansion (-4.1% YoY revenue growth, N/M PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates.
Technical & Structure Timing Caution: STEM is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 22.9); meanwhile DNA is in a Breakdown options structure phase (RSI 37.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Competes within the Utilities - Renewable value chain with $7.1M market capitalization and -12.1% operating margin.
OpEx & R&D Reinvestment59.7% of Rev ($87M)
90D Engineering Disclosures0 Published
DNA Moat ProfileCyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $531.5M market capitalization and -202.5% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ STEM vs DNA Key Questions & Quantitative Answers
As of Nov 20, 2026, Ginkgo Bioworks Holdings, Inc. (DNA) captures the overall head-to-head institutional edge over Stem, Inc. (STEM) on higher Unified Composite conviction (52.1/100 HOLD vs. 42.4/100 HOLD) after splitting the core matrix 5–3 (led by Valuation Multiples, Options & Positioning), while STEM wins 4–2 across the 6-pillar growth and valuation breakdown. STEM trades at $0.64 (N/M Forward P/E, -12.1% operating margin) versus DNA at $7.46 (N/M Forward P/E, -202.5% operating margin). Growth vs. Quality Trade-Off: DNA earns the overall head-to-head edge with a stronger Unified Composite Score (52.1/100 HOLD vs. STEM 42.4/100 HOLD) and 3.12β · 152% Vol risk profile, whereas STEM leads top-line expansion (-4.1% YoY revenue growth, N/M PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: STEM is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 22.9); meanwhile DNA is in a Breakdown options structure phase (RSI 37.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
STEM leads the Growth & Scale pillar: STEM posts -4.1% YoY revenue growth and +0.0% YoY earnings growth on $146M TTM revenue (47.6% gross margin, -12.1% operating margin), compared with DNA at -5.7% YoY revenue growth and +0.0% YoY earnings growth on $131M TTM revenue (69.8% gross margin, -202.5% operating margin). Across the 7-period historical trajectory (FY2019 to FY2025), STEM cumulative revenue shifted +700.0% while DNA shifted +240.0%. In operating R&D and SG&A reinvestment, STEM deploys 59.7% of Rev ($87M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for DNA.
DNA screens cheaper on headline valuation multiples. STEM trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (4.9% FCF margin), whereas DNA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 6.5x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against STEM (-5920.8% ROE) versus DNA (-58.2% ROE) capital efficiency.
In options market volatility and institutional positioning, STEM carries 175.8% implied volatility (39th %ile, Balanced (25th–60th %ile)), a 0.14x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (4.60β · 234% Vol realized risk). By comparison, DNA carries 101.7% implied volatility (22nd %ile, Compressed (<25th %ile)), a 0.78x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (3.12β · 152% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.